patient
Leo Luznik, MD
Sydney X. Lu, MD
Thomas P. Loughran Jr, MD
Bradley H. Lewis, MD
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: Phase 2 ESCALATE trial
Key Points
Eltrombopag combined with IST demonstrated a trend towards a favorable ORR in pediatric patients with r/r SAA.
The PK profile for eltrombopag was similar to that observed in patients with ITP, and no unexpected safety signals were observed in children
Donor regulatory T-cell therapy to prevent graft-versus-host disease
Key Points
Treg-engineered donor graft prevents acute and chronic GVHD.
Patients treated with Treg-engineered graft who develop GVHD respond to primary corticosteroid therapy at a high rate.
Taking Charge of My Care and Advocacy Following a Cancer Diagnosis
After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis.
Prognostic Significance of Monocytic-like Phenotype in AML patients treated with Venetoclax and Azacytidine
Key Points
The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT
Abstract





